David Potter

Associate Professor

University of Minnesota

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Potter is an Associate Professor at the University of Minnesota, USA. His research primarily focuses on breast cancer, with recent articles addressing topics such as international multidisciplinary tumor boards, the impact of body mass index on chemotherapy responses, and innovative treatments like neoadjuvant therapies and immune checkpoint inhibitors. He is also involved in examining the long-term effects of treatments on breast cancer survivors and the implications of COVID-19 on cancer trials.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (1)

W. Fraser Symmans

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Potter

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Association for Academic Surgery Development of an International Virtual Multidisciplinary Tumor Board for Breast Cancer in Mongolia

Cooling inflammation while potentiating immune checkpoint inhibition: Enhancing the benefit-risk ratio of immuno- oncology therapy

Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery

Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time

Evaluation of Tucatinib plus (Paclitaxel plus Pertuzumab plus Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes

Collaborators (1)

W. Fraser Symmans

Make your next move.